Axel Schambach spends much of his time researching Cell biology, Genetic enhancement, Immunology, Vector and Viral vector. His Cell biology research includes elements of Transcription factor and Cellular differentiation. His work deals with themes such as Transgene, Bioinformatics, Pathology, Wiskott–Aldrich syndrome and Gene targeting, which intersect with Genetic enhancement.
His studies deal with areas such as Cancer research, Severe combined immunodeficiency and Transplantation as well as Immunology. His Vector research incorporates elements of Insertional mutagenesis, Epigenetics and Long terminal repeat. His study looks at the relationship between Viral vector and fields such as Molecular biology, as well as how they intersect with chemical problems.
Axel Schambach mainly investigates Cell biology, Genetic enhancement, Haematopoiesis, Viral vector and Cancer research. His Cell biology research incorporates themes from Cellular differentiation, Transcription factor, Molecular biology, Induced pluripotent stem cell and Transduction. His Genetic enhancement study combines topics from a wide range of disciplines, such as Vector, Transgene, Transplantation and Virology.
His Vector research includes themes of Insertional mutagenesis and Long terminal repeat. In his study, which falls under the umbrella issue of Haematopoiesis, Interleukin 12 is strongly linked to Immunology. Axel Schambach has included themes like Cell, Chimeric antigen receptor, Immunotherapy and Bone marrow in his Cancer research study.
His primary scientific interests are in Cancer research, Genetic enhancement, Cell biology, Haematopoiesis and Progenitor cell. The study incorporates disciplines such as Cell, T cell, Chimeric antigen receptor, Immune system and Antigen in addition to Cancer research. His Genetic enhancement research integrates issues from CD34, Clinical trial, Viral vector and Disease.
Axel Schambach combines subjects such as Severe combined immunodeficiency and Immunology with his study of Viral vector. His Cell biology study combines topics in areas such as Embryonic stem cell, Induced pluripotent stem cell and DNA methylation. His Haematopoiesis study is related to the wider topic of Stem cell.
Axel Schambach mostly deals with Cancer research, Chimeric antigen receptor, Cell biology, Viral vector and Genetic enhancement. In Cancer research, Axel Schambach works on issues like Transduction, which are connected to Reporter gene and Haematopoiesis. His Chimeric antigen receptor study integrates concerns from other disciplines, such as Cytotoxic T cell, Natural killer cell and Hematopoietic stem cell.
His Cell biology research is multidisciplinary, incorporating perspectives in Transgene, Cytokine and Induced pluripotent stem cell. The Viral vector study combines topics in areas such as Tumor microenvironment and CD34, Stem cell. Axel Schambach studies Gene delivery, a branch of Genetic enhancement.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity
Christian Jörg Braun;Kaan Boztug;Anna Paruzynski;Maximilian Witzel.
Science Translational Medicine (2014)
Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors
Ute Modlich;Susana Navarro;Daniela Zychlinski;Tobias Maetzig.
Molecular Therapy (2009)
Skin tissue generation by laser cell printing.
Lothar Koch;Andrea Deiwick;Sabrina Schlie;Stefanie Michael.
Biotechnology and Bioengineering (2012)
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Ute Modlich;Jens Bohne;Manfred Schmidt;Christof von Kalle.
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Salima Hacein-Bey-Abina;Sung Yun Pai;H. Bobby Gaspar;Myriam Armant.
The New England Journal of Medicine (2014)
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage.
Jianwei Wang;Qian Sun;Yohei Morita;Hong Jiang.
Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors
Daniela Zychlinski;Axel Schambach;Ute Modlich;Tobias Maetzig.
Molecular Therapy (2008)
Long noncoding RNA Chast promotes cardiac remodeling.
Janika Viereck;Regalla Kumarswamy;Ariana Foinquinos;Ke Xiao.
Science Translational Medicine (2016)
The phenotype of human STK4 deficiency
Hengameh Abdollahpour;Giridharan Appaswamy;Daniel Kotlarz;Daniel Kotlarz;Jana Diestelhorst;Jana Diestelhorst.
Gene therapy on the move
Kerstin B. Kaufmann;Hildegard Büning;Anne Galy;Axel Schambach;Axel Schambach.
Embo Molecular Medicine (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: